ArticleJournal of clinical microbiology2013
Quantification of viral loads lower than 50 copies per milliliter by use of the Cobas AmpliPrep/Cobas TaqMan HIV-1 test, version 2.0, can predict the likelihood of subsequent virological rebound to >50 copies per milliliter.
Article in Journal of clinical microbiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Longitudinal associations between depression, substance use, and immune activation and inflammation: A secondary analysis of men who have sex with men living with HIV in Brazil (HPTN 063).Brain, behavior, and immunity · 2026Article
- The Perils of Overly Sensitive Viral Load Testing for Persons With Human Immunodeficiency Virus.Open forum infectious diseases · 2023Article
- Influencing factors and adverse outcomes of virologic rebound states in anti-retroviral-treated individuals with HIV infection.Journal of virus eradication · 2023Review
- Limits of Detection and Limits of Infection: Quantitative HIV Measurement in the Era of U = U.The journal of applied laboratory medicine · 2021Article
- Review
- A Simple Phosphate-Buffered-Saline-Based Extraction Method Improves Specificity of HIV Viral Load Monitoring Using Dried Blood Spots.Journal of clinical microbiology · 2017Article
- Evaluation of the Aptima HIV-1 Quant Dx Assay Using Plasma and Dried Blood Spots.Journal of clinical microbiology · 2016Article
- HIV Replication at Low Copy Number and its Correlation with the HIV Reservoir: A Clinical Perspective.Current HIV research · 2015Review
- Clinical Applications of Quantitative Real-Time PCR in Virology.Methods in microbiology · 2015Article
- Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients.Antimicrobial agents and chemotherapy · 2014Article
- Ability of two commercially available assays (Abbott RealTime HIV-1 and Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Version 2.0) to quantify low HIV-1 RNA Levels (<1,000 copies/milliliter): comparison with clinical samples and NIBSC working reagent for nucleic acid testing assays.Journal of clinical microbiology · 2014Article
- Residual viremia is preceding viral blips and persistent low-level viremia in treated HIV-1 patients.PloS one · 2014Article
- Characterizing Patients with Very-Low-Level HIV Viremia: A Community-Based Study.Journal of the International Association of Providers of AIDS CareArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
After 1 year of follow-up, patients on HAART with a baseline viral load (VL) of <20 copies/ml showed significantly lower odds of virological rebound to two consecutive VLs of >50 copies/ml than those with baseline VLs of 20 to 39 and 40 to 49 (P < 0.001). The time to virological rebound was also significantly shorter (P < 0.001) for the groups with baseline VLs of 20 to 39 and 40 to 49.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.